Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Cardiology

The Long View: Survivorship & Monitoring with FIDC

At a Glance

Living with familial isolated dilated cardiomyopathy requires a lifelong commitment to heart health. Long-term care focuses on regular monitoring with echocardiograms, practicing safe, moderate exercise tailored to your genetics, and watching for warning signs like sudden weight gain.

Living with Familial Isolated Dilated Cardiomyopathy (FIDC) is less about a single event and more about a lifelong commitment to heart health [1]. While the diagnosis is chronic, many patients reach a state of “clinical stability” where their heart function is managed and their symptoms are minimal [2]. Success in the long term requires a shift in perspective—treating your care like a marathon rather than a sprint [3].

Your Long-Term Surveillance Roadmap

Once your medications are optimized, your care moves into a “maintenance phase.” Because FIDC can change over time, your team will use a variety of tools to keep a close watch on your heart’s structure and rhythm [4][5].

  • Echocardiogram: Typically performed every 1–2 years once you are stable, though this may be more frequent if your medications are being adjusted [6][5].
  • Cardiac MRI (CMR): This may be repeated every 3–5 years to check for changes in heart muscle scarring (LGE), which can help refine your risk for heart rhythm problems [7][8].
  • Heart Rhythm Monitoring (Holter/Patch): Even if you don’t feel palpitations, your doctor may ask you to wear a heart monitor for 24–48 hours once a year. This “checks under the hood” for silent electrical issues [6][9].

Exercise and Lifestyle: Finding the Right Balance

Physical activity is a powerful medicine for the heart, but it must be tailored to your specific genetic makeup [10][11].

  • The Power of Moderate Exercise: For most with FIDC, moderate activities like walking, cycling, or swimming are highly encouraged and can improve your quality of life [10].
  • Genetic Restrictions: If you have specific high-risk mutations like LMNA, FLNC, or RBM20, your doctor may advise against high-intensity or competitive sports [12][13]. This is because intense physical stress can sometimes trigger the very heart rhythm issues we are trying to prevent [14][15].
  • Alcohol and Toxins: In general, it is best to limit alcohol. Excessive intake can directly weaken the heart muscle, potentially making your FIDC harder to manage [16][17]. Smoking should be avoided entirely, as it is a known trigger for worsening heart disease [18].

Managing the Psychological Burden

It is completely normal to feel “Scan Anxiety” (Scanxiety) in the days leading up to an appointment or test [19]. Chronic monitoring can feel like you are constantly waiting for bad news.

  • Focus on Trends, Not Single Numbers: Ejection fraction (LVEF) can fluctuate slightly from test to test based on hydration or stress levels. Look for the “big picture” trend with your doctor rather than panicking over a 2% change [20].
  • Know Your Warning Signs: Empower yourself by knowing what “worsening” actually looks like. Contact your team if you notice sudden weight gain (more than 2–3 lbs in a day), increased shortness of breath when lying flat, or new palpitations (a racing or skipping heart) [21][22].
  • Build Your Support System: Whether it’s a support group of others with genetic heart disease or a therapist, having a space to talk about the “weight” of the diagnosis is just as important as your medication [23].

Remember, the goal of long-term monitoring isn’t just to catch problems—it’s to confirm that your treatment is working and to keep you living the life you want to lead [1][24].

Return to the Welcome to Your FIDC Resource Guide to review other sections.

Common questions in this guide

How often do I need tests to monitor my FIDC?
Once your condition is stable, you will typically need an echocardiogram every one to two years to check your heart function. Your doctor may also recommend a cardiac MRI every few years and an annual heart rhythm monitor to look for hidden electrical issues.
Is it safe to exercise if I have familial isolated dilated cardiomyopathy?
Moderate exercise like walking, swimming, or cycling is highly encouraged for most people with FIDC and can improve your quality of life. However, if you have specific high-risk genetic mutations, your cardiologist may advise against high-intensity or competitive sports to protect your heart.
What warning signs should I watch for between my cardiology appointments?
You should contact your healthcare team if you notice sudden weight gain of more than two to three pounds in a day, which can indicate fluid buildup. Other important warning signs include increased shortness of breath when lying flat or new heart palpitations.
Can I drink alcohol if I have FIDC?
It is generally best to limit your alcohol intake if you have familial isolated dilated cardiomyopathy. Excessive alcohol can directly weaken the heart muscle, making your condition harder to manage and potentially worsening your symptoms.
Why does my ejection fraction change slightly on different tests?
Your ejection fraction can naturally fluctuate a few percentage points from test to test based on factors like hydration or your stress levels at the time. Doctors look at the big picture and long-term trends rather than reacting to a minor change on a single echocardiogram.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific genetic mutation (e.g., LMNA or FLNC), is there a maximum heart rate I should stay under during exercise?
  2. 2.Am I safe to perform resistance training (lifting weights), or should I stick to aerobic exercise like walking?
  3. 3.How often do I need a Holter monitor to check for 'silent' arrhythmias that I might not feel?
  4. 4.How much alcohol, if any, is considered safe for someone with my specific heart function?
  5. 5.If my LVEF improves significantly on medication, will we still do an Echo every year?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy.

    Vita T, Gräni C, Abbasi SA, et al.

    JACC. Cardiovascular imaging 2019; (12(8 Pt 2)):1659-1669 doi:10.1016/j.jcmg.2018.08.021.

    PMID: 30448130
  2. 2

    Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.

    Halliday BP, Wassall R, Lota AS, et al.

    Lancet (London, England) 2019; (393(10166)):61-73 doi:10.1016/S0140-6736(18)32484-X.

    PMID: 30429050
  3. 3

    Myocardial Tissue Reverse Remodeling After Guideline-Directed Medical Therapy in Idiopathic Dilated Cardiomyopathy.

    Xu Y, Li W, Wan K, et al.

    Circulation. Heart failure 2021; (14(1)):e007944 doi:10.1161/CIRCHEARTFAILURE.120.007944.

    PMID: 33185117
  4. 4

    Diverse Concepts in Definitions of Dilated Cardiomyopathy: Theory and Practice.

    Myers MC, Breznen B, Zhong Y, et al.

    Cardiology research 2024; (15(5)):319-329 doi:10.14740/cr1679.

    PMID: 39420975
  5. 5

    Genetic Screening Reveals Heterogeneous Clinical Phenotypes in Patients with Dilated Cardiomyopathy and Troponin T2 Variants.

    Weis A, Krueck S, Dombrowsky G, et al.

    Journal of personalized medicine 2023; (13(4)) doi:10.3390/jpm13040611.

    PMID: 37108997
  6. 6

    Role of family history and clinical screening in the identification of families with idiopathic dilated cardiomyopathy in Johannesburg, South Africa.

    Bailly C, Henriques S, Tsabedze N, Krause A

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2019; (109(9)):673-678 doi:10.7196/SAMJ.2019.v109i9.13936.

    PMID: 31635593
  7. 7

    Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle.

    Porcari A, De Luca A, Grigoratos C, et al.

    Heart failure reviews 2022; (27(1)):49-69 doi:10.1007/s10741-020-09986-0.

    PMID: 32564329
  8. 8

    Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy: Role of Multimodality Imaging.

    Stătescu C, Ureche C, Enachi Ș, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040625.

    PMID: 33808474
  9. 9

    The contribution of cardiopulmonary exercise testing in the familial screening for dilated and non-dilated left ventricular cardiomyopathies: case series.

    Del Mestre E, Capovilla TM, Paldino A, et al.

    European heart journal. Case reports 2025; (9(4)):ytaf162 doi:10.1093/ehjcr/ytaf162.

    PMID: 40302978
  10. 10

    Impact of exercise training on clinical outcomes and quality of life in chronic congestive heart failure: A systematic review and meta-analysis.

    Al Hennawi H, Bedi A, Khan MK, et al.

    Current problems in cardiology 2024; (49(10)):102756 doi:10.1016/j.cpcardiol.2024.102756.

    PMID: 39074671
  11. 11

    Exercise Training and Heart Failure: A Review of the Literature.

    Morris JH, Chen L

    Cardiac failure review 2019; (5(1)):57-61 doi:10.15420/cfr.2018.31.1.

    PMID: 30847247
  12. 12

    Laminopathies: should Wenckebach be a cause for concern? A case report.

    Sen G, Jackson T

    European heart journal. Case reports 2021; (5(11)):ytab331 doi:10.1093/ehjcr/ytab331.

    PMID: 34816081
  13. 13

    Lamin missense mutations-the spectrum of phenotype variability is increasing.

    Captur G, Bilińska Z, Arbustini E

    European journal of heart failure 2018; (20(10)):1413-1416 doi:10.1002/ejhf.1290.

    PMID: 30178466
  14. 14

    Exercise is Associated With Impaired Left Ventricular Systolic Function in Patients With Lamin A/C Genotype.

    Skjølsvik ET, Hasselberg NE, Dejgaard LA, et al.

    Journal of the American Heart Association 2020; (9(2)):e012937 doi:10.1161/JAHA.119.012937.

    PMID: 31957533
  15. 15

    Filamin C in cardiomyopathy: from physiological roles to DNA variants.

    Song S, Shi A, Lian H, et al.

    Heart failure reviews 2022; (27(4)):1373-1385 doi:10.1007/s10741-021-10172-z.

    PMID: 34535832
  16. 16

    Moderate excess alcohol consumption and adverse cardiac remodelling in dilated cardiomyopathy.

    Tayal U, Gregson J, Buchan R, et al.

    Heart (British Cardiac Society) 2022; (108(8)):619-625 doi:10.1136/heartjnl-2021-319418.

    PMID: 34380661
  17. 17

    Heart failure with reduced ejection fraction: What's new in the 2022 guideline?

    Kittleson MM

    Cleveland Clinic journal of medicine 2023; (90(4)):215-220 doi:10.3949/ccjm.90a.22101.

    PMID: 37011962
  18. 18

    Association between cardiovascular risk factors and dilated and hypertrophic cardiomyopathy: Mendelian randomization analysis.

    Zou C, Zou H, Jiang Y, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2025; (35(1)):103752 doi:10.1016/j.numecd.2024.09.022.

    PMID: 39455334
  19. 19

    Analysis of the current situation and influencing factors of internal perceptions in patients with chronic heart failure at the county level.

    Yu M, Ge J, Jiang L, et al.

    Frontiers in psychology 2025; (16()):1618068 doi:10.3389/fpsyg.2025.1618068.

    PMID: 40746453
  20. 20

    Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography.

    Mathew T, Williams L, Navaratnam G, et al.

    Echo research and practice 2017; (4(2)):G1-G13.

    PMID: 28592613
  21. 21

    Right ventricular failure after LVAD support: A challenging case of bridge to heart transplantation in end-stage dilated cardiomyopathy.

    Suciu H, Anitei ED, Calburean P, Harpa MM

    Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2026; (12(1)):102-109 doi:10.2478/jccm-2025-0038.

    PMID: 41704333
  22. 22

    Ventricular Standstill in a Patient With a Left Ventricular Assist Device.

    Fukunaga N, Nedadur R, Badiwala MV, et al.

    The Annals of thoracic surgery 2019; (108(3)):e153-e155 doi:10.1016/j.athoracsur.2019.01.066.

    PMID: 30853593
  23. 23

    The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy-A systematic review and meta-analysis.

    Cirino AL, Harris SL, Murad AM, et al.

    Journal of genetic counseling 2022; (31(6)):1290-1305 doi:10.1002/jgc4.1604.

    PMID: 35799446
  24. 24

    Family Screening in Dilated Cardiomyopathy: Prevalence, Incidence, and Potential for Limiting Follow-Up.

    Vissing CR, Espersen K, Mills HL, et al.

    JACC. Heart failure 2022; (10(11)):792-803 doi:10.1016/j.jchf.2022.07.009.

    PMID: 36328645

This page provides long-term monitoring and lifestyle information for FIDC for educational purposes only. Always consult your cardiologist before starting a new exercise routine or changing your care plan.

Get notified when new evidence is published on Familial isolated dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.